Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the healthcare system and physical activity behaviours including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided. Graphical abstract Supplementary Information The online version of this article (10.1007/s00125-022-05787-2) contains peer-reviewed but unedited supplementary material.

Advancing a causal role of type 2 diabetes and its components in developing macro‐ and microvascular complications via genetic studies

“…This is interesting, as there appears to be an increasing focus on treating excess weight in the management of type 2 diabetes, both for remission 53 and potentially reduction in multiple complications 54 . This focus on a need to target excess weight more in type 2 diabetes has also been recognized in the recently updated ADA/EASD recommendations 55 . The work summarized also provide more evidence for a multifactorial approach (targeting not only glycaemia but also blood pressure, excess weight and lipids) to treating type 2 diabetes to prevent complications.…”

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence

“…Numerous CV trials have reported improvements in CV outcomes in patients treated with GLP-1 RAs. 49,50 GLP-1 has pleiotropic CV effects, including anti-inflammatory effects, cardioprotection in ischemia, and decreased platelet aggregation. 38 In addition, activation of GLP-1R resulted in various anti-atherosclerotic effects, e.g., reversing endothelial dysfunction (stimulates nitric oxide [NO] production and endothelial NO synthase [eNOS] activation, eliciting vasorelaxation in arterial endothelium), improving vascular smooth muscle cell dysfunction, reducing macrophage inflammation and foam cell formation, inhibiting NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) inflammasome and improving cardiomyocyte/cardiac fibroblast dysfunction.…”

The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease

“…В соответствии с консенсусом Европейской ассоциации по изучению диабета (European Association for the Study of Diabetes, EASD) и Американской диабетологической ассоциации (American Diabetes Association, ADA) 2022 г. пиоглитазон в качестве сахароснижающего препарата в лечении СД2 находится в числе приоритетных у лиц с наличием или высоким риском ассоциированных СС-заболеваний, а также у пациентов, не страдающих СС-заболеваниями, с позиции высокой эффективности гликемического контроля (рис. 2) [67].…”